{
  "EGFR": {
    "full_name": "Epidermal Growth Factor Receptor",
    "protein_class": "Receptor tyrosine kinase",
    "chromosome": "7p12",
    "diseases": [
      "NSCLC",
      "Glioblastoma",
      "Colorectal cancer"
    ],
    "druggability_tier": "Tier 1",
    "known_inhibitors": [
      "Gefitinib",
      "Erlotinib",
      "Osimertinib"
    ],
    "market_size_m": 4500,
    "patent_landscape": "Crowded"
  },
  "ERBB2": {
    "full_name": "Erb-B2 Receptor Tyrosine Kinase 2",
    "protein_class": "Receptor tyrosine kinase",
    "chromosome": "17q12",
    "diseases": [
      "Breast cancer",
      "Gastric cancer"
    ],
    "druggability_tier": "Tier 1",
    "known_inhibitors": [
      "Trastuzumab",
      "Pertuzumab",
      "T-DM1"
    ],
    "market_size_m": 3200,
    "patent_landscape": "Moderately crowded"
  },
  "KRAS": {
    "full_name": "KRAS Proto-Oncogene GTPase",
    "protein_class": "Small GTPase",
    "chromosome": "12p12.1",
    "diseases": [
      "Pancreatic cancer",
      "Colorectal cancer",
      "NSCLC"
    ],
    "druggability_tier": "Tier 2",
    "known_inhibitors": [
      "Sotorasib",
      "Adagrasib"
    ],
    "market_size_m": 8900,
    "patent_landscape": "Emerging competition"
  },
  "TP53": {
    "full_name": "Tumor Protein P53",
    "protein_class": "Transcription factor",
    "chromosome": "17p13.1",
    "diseases": [
      "Pan-cancer",
      "Li-Fraumeni syndrome"
    ],
    "druggability_tier": "Tier 3",
    "known_inhibitors": [
      "APR-246",
      "PRIMA-1"
    ],
    "market_size_m": 15000,
    "patent_landscape": "Limited competition"
  },
  "MET": {
    "full_name": "MET Proto-Oncogene Receptor Tyrosine Kinase",
    "protein_class": "Receptor tyrosine kinase",
    "chromosome": "7q31.2",
    "diseases": [
      "NSCLC",
      "Glioblastoma",
      "Renal cell carcinoma"
    ],
    "druggability_tier": "Tier 1",
    "known_inhibitors": [
      "Crizotinib",
      "Cabozantinib"
    ],
    "market_size_m": 2100,
    "patent_landscape": "Moderate competition"
  }
}